

DBeQ, p97 inhibitor

IUPAC Name: 2,4-dibenzylaminoquinazoline

Cat. # SI9835

Background: DBeQ is a cell permeable, potent, selective and reversible inhibitor of the AAA-ATPase p97 (ATPase associated with diverse cellular activities). $K_i=3.2 \mu\text{M}$. DBeQ blocks both ubiquitin dependent and endoplasmic reticulum-associated degradation pathways, protein clearance pathways, and activates caspases -3 and -7 inducing apoptosis.


Application: Cell-based studies of ubiquitination and protein dislocation

Product Information:

CAS No.	n/a
Purity:	99% by TLC/NMR
Molecular Weight:	340.4 Da
Physical State:	Yellow Powder
Quantity:	10 or 25 mg
Solubility:	DMSO (25mg/ml)
Storage:	Store desiccated as supplied at 4°C for 2 years. Store solution at -20 °C for up to 2 months; light sensitive

Formula:

C₂₂H₂₀N₄



References

1. P. Bastola, L. Neums, F. Schoenen and J. Chien, "VCP inhibitors induce endoplasmic reticulum stress, cause cell cycle arrest, trigger caspase-mediated cell death and synergistically kill ovarian cancer cells in combination with Salubrinal", *Molecular Oncology*, vol. 10, no. 10, pp. 1559-1574, 2016.
2. H. Auner, A. Moody, T. Ward, M. Kraus, E. Milan, P. May, A. Chaidos, C. Driessen, S. Cenci, F. Dazzi, A. Rahemtulla, J. Apperley, A. Karadimitris and N. Dillon, "Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells", *PLoS ONE*, vol. 8, no. 9, p. e74415, 2013.

All products are for research use only • Not intended for human or animal diagnostic or therapeutic uses
Copyright © 2017 LifeSensors, Inc. All Rights Reserved